WATERTOWN, Mass., July 30, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that the Company will report financial results for its second quarter ended June 30, 2019 on Tuesday, August 6, 2019, after the close of the market.
Aileron is a clinical-stage biopharmaceutical company advancing a proprietary platform of cell-permeating alpha-helical peptides that address the most important intracellular targets in oncology and other therapeutic areas. The stabilized helical structure of our peptides allows the design of cell-permeating therapeutic agents with large molecular surfaces for optimal target binding properties, resulting in unique drugs like ALRN-6924. For more information, please visit www.aileronrx.com.
Don Dougherty, CFO
Hans C. Vitzthum
LifeSci Advisors, LLC.
Source: Aileron Therapeutics